palisadebio.com (PALI): רווח נקי למניה ב-12 החודשים האחרונים

Palisade Bio, Inc. (PALI) is implementing AI and robotics to identify targets for gastrointestinal therapy. The asset's value growth is supported by PALI-2108 trials and a unique platform, with development proceeding through academic alliances. The 12-month EPS change demonstrates yield dynamics, where -0.22 is the current level of the indicator, helping to identify capital drawdown risks in a timely manner.

Fundamental analysis of eps_ttm_co minimizes the risk of capital losses when evaluating undervalued assets. For Palisade Bio, Inc. (PALI), which lacks operating income and relies on external financing, this indicator is critically important. The metric is calculated as the ratio of total annual net income to the number of outstanding common shares. By analyzing the current eps TTM level, an investor determines the actual return per share of the business, allowing for the timely detection of capital degradation.